Videolaryngoscope vs Regular Laryngoscope for Infant Intubation
(NasoVISI Trial)
Trial Summary
What is the purpose of this trial?
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal intubation (NTI) first attempt success rate using VL vs. DL in infants 0-365 days of age presenting for cardiothoracic surgery and cardiac catheterizations.
Will I have to stop taking my current medications?
The trial protocol does not specify whether participants need to stop taking their current medications. However, it mentions that a neuromuscular blocking drug will be used before intubation as part of standard care.
What data supports the effectiveness of this treatment for infant intubation?
Research suggests that videolaryngoscopy (VL) can be an effective tool for training inexperienced medical staff in tracheal intubation, as it improves success rates and reduces intubation time compared to direct laryngoscopy (DL). This indicates that VL might be beneficial for infant intubation, especially for those new to the procedure.12345
Is nasotracheal intubation with videolaryngoscopy safe for infants?
How does nasotracheal intubation with videolaryngoscopy differ from other treatments for infant intubation?
Nasotracheal intubation with videolaryngoscopy (VL) offers an indirect view of the airway, which can be especially helpful for inexperienced users, as it allows them to see the airway on a screen without needing to align the oral and throat passages. This can lead to higher success rates and shorter intubation times for novices compared to direct laryngoscopy (DL), which requires direct line-of-sight and more skill.13457
Research Team
Annery Garcia-Marcinikiewicz, MD
Principal Investigator
The Children Hospital of Philadelphia
Eligibility Criteria
This trial is for infants aged 0-365 days who need general anesthesia for elective cardiothoracic surgery or cardiac catheterization. They must be scheduled to receive a muscle relaxant before intubation and have no history of difficult intubation, abnormal airway, preoperative breathing tubes, or tracheostomy. Infants born before 36 weeks gestation or weighing less than 2 kg are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo nasotracheal intubation using either Videolaryngoscopy or Direct Laryngoscopy
Follow-up
Participants are monitored for complications and success rate of intubation
Treatment Details
Interventions
- Nasotracheal Intubation
Nasotracheal Intubation is already approved in United States for the following indications:
- Cardiothoracic surgery
- Cardiac catheterizations
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital of Philadelphia
Lead Sponsor
Children's Healthcare of Atlanta
Collaborator
Vanderbilt University Medical Center
Collaborator
Children's Hospital Colorado
Collaborator
Dell Children's Medical Center of Central Texas
Collaborator
Seattle Children's Hospital
Collaborator
Baylor College of Medicine
Collaborator
Children's Medical Center Dallas
Collaborator
Children's National Research Institute
Collaborator